Commissioner Oh Yu-Kyoung of the Ministry of Food and Drug Safety (MFDS) announced on the 7th that MFDS has approved Roche Korea's rare disease drug 'Columvi (glofitamab)' for the treatment of diffuse large B cell lymphoma (DLBCL).

The drug is a CD20/CD3 bispecific monoclonal antibody that binds to CD3 on the surface of T cells and CD20 on B cells. Columvi provides a new treatment opportunity for DLBCL patients who had relapsed or were refractory after two or more lines of systemic therapies.

Columvi (Glofitamab) binds to the CD3 and activates the T cells, it simultaneously binds to CD20, to redirecting B cells closer to activated T cells and inducing cytosis.

The MFDS s